Hengrui Pharma announced that it has reached an agreement with biopharmaceutical company GSK to grant paid licenses to GSK for the global exclusive rights of the HRS-9821 project (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) and the exclusive option for the global exclusive license of up to 11 projects.
GSK will pay Hengrui $500 million as an initial payment. If all projects are granted exclusive options and all milestones are achieved, Hengrui will be eligible to receive a potential total amount of around $12 billion based on successful development, registration, and sales milestone payments.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。